Emory University has created an endowed distinguished professorship honoring George Painter for his life-saving work in developing critical medicines including molnupiravir, which is now approved globally for the treatment of SARS-CoV-2.
Emory University has created an endowed distinguished professorship honoring George Painter for his life-saving work in developing critical medicines including molnupiravir, which is now approved globally for the treatment of SARS-CoV-2.
Faculty entrepreneurs and their discoveries were recognized at the Office of Technology Transfer’s 16th Annual Celebration of Technology and Innovation. Three new awards were added this year, for a total of seven categories.
Researcher and inventor Dennis Liotta is the 2022 recipient of the Perkin Medal, the highest honor a scientist can receive for contributions to applied chemistry in the U.S. His discoveries include transformative treatments for HIV and hepatitis B.
On Dec. 23, molnupiravir, an investigational oral antiviral drug invented by scientists at Emory University, received Emergency Use Authorization from the FDA for the treatment of COVID-19.
A FDA panel voted in favor of a proposed Emergency Use Authorization for the antiviral drug molnupiravir.
An Emory-invented antiviral treatment for COVID-19 has been authorized by British regulators, making molnupiravir the first antiviral pill approved for use against SARS-CoV-2. An emergency use application is also under consideration by the U.S. Food and Drug Administration.
The Medicines Patent Pool and Merck have entered into a licensing agreement to facilitate affordable access for molnupiravir, an investigational oral antiviral COVID-19 medicine, in 105 low- and middle-income countries.
With Merck’s findings that Emory-discovered molnupiravir may significantly reduce the risk of hospitalization or death from COVID-19, Emory President Gregory L. Fenves joins epidemiologist Jodie Guest in a conversation about Emory’s history of research innovation.
Molnupiravir, an investigational oral antiviral drug discovered by Emory researchers, appears to significantly reduce the risk of hospitalization or death in patients with mild to moderate COVID-19, according to interim data from a Phase 3 study.
To address the intensifying COVID-19 crisis in India, the pharmaceutical company Merck has agreed to facilitate the manufacture and distribution of molnupiravir, an investigational antiviral drug that was discovered at Emory.
An antiviral drug initially discovered by Emory’s non-profit drug development company DRIVE appears safe and reduces SARS-CoV-2 to undetectable levels in COVID-19 patients after five days of administration, according to data from a Phase II clinical trial.
An oral antiviral discovered and developed at Emory can begin human trials. EIDD-2801 has shown promise for treating COVID-19.
Scientists are hopeful that a new drug called EIDD-2801 could change the way doctors treat COVID-19. The drug shows promise in reducing lung damage and has finished testing in mice. It will soon move to human clinical trials.
Ridgeback Biotherapeutics will license EIDD-2801, a potential drug against coronaviruses, from Emory's DRIVE and take it through clinical trials.
Drug Innovation Ventures at Emory is developing an antiviral compound, discovered here, that could potentially treat the new coronavirus currently spreading around the globe.